secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001437749-23-027034
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO subsidiary ModeX awarded $59M BARDA contract for multispecific antibody against SARS-CoV-2, up to $168M total
--------------------------------------------------------------------------------

- ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.
- Up to $109M additional contingent on milestones for developing antibodies against influenza and other viral pathogens.
- Total potential contract value $168M; part of HHS' Project NextGen for innovative COVID-19 vaccines and therapeutics.
- Gene-based delivery methods (mRNA/DNA vectors) will be developed to leverage body's natural protein production.
- In March 2023, ModeX entered exclusive worldwide license with Merck for Epstein-Barr virus vaccine candidate MDX2201.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/0001437749-23-027034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/opk20230928c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer